EPHX2 and neoplasm: Dual sEH/COX2 inhibition counter-regulates a chemotherapy-induced cytokine storm and synergizes with front-line cancer therapies such as chemotherapy and enzalutamide to reduce tumor growth (9, 11, 60, 61).